BioSpace News Archive

Relmada Therapeutics, Inc. announced that it will report its financial results for the first quarter ended March 31, 2024 after the market close on Wednesday, May 8, 2024.

ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin vascular targeted photodynamic (VTP) therapy to treat a range of solid tumors, today announced positive preliminary results from ENLIGHTED (ENdoluminal LIGHT ActivatED), its ongoing pivotal Phase 3 clinical trial evaluating Padeliporfin VTP in patients with low-grade upper tract urothelial cancer (UTUC).

Apogee Therapeutics, Inc. announced that Michael Henderson, M.D., Chief Executive Officer and Jane Pritchett Henderson, Chief Financial Officer, will participate in a fireside chat at the 2024 Bank of America Healthcare Conference on Wednesday, May 15, 2024 at 3:40 p.m. P.T. / 6:40 p.m. E.T.

Telesis Bio Inc., a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, announced that it will effect a 1-for-18 reverse stock split of its common stock.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2024 and provided a corporate update.

RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, reported financial results for the three months ended March 31, 2024.

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the quarter ended March 31, 2024 and provided a corporate update.

OrthoPediatrics Corp., a company focused exclusively on advancing the field of pediatric orthopedics, announced its financial results for the first quarter ended March 31, 2024.

Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the first quarter ended March 31, 2024.

Blueprint Medicines Corporation, announced that, effective May 1, 2024, the Compensation Committee of Blueprint Medicines’ Board of Directors granted non-qualified stock options to purchase an aggregate of 6,400 shares of its common stock and an aggregate of 3,200 restricted stock units to two new employees under Blueprint Medicines’ 2020 Inducement Plan.